Pulmonx Corporation (NASDAQ: LUNG) Stock Competitors & Peer Comparison

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, ABT has a market cap of 201.8B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while ABT trades at $116.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas ABT's P/E ratio is 22.39. In terms of profitability, LUNG's ROE is -0.97%, compared to ABT's ROE of +0.11%. Regarding short-term risk, LUNG is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check ABT's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, LUNG's ROE is -0.97%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, LUNG is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check BSX-PA's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, SYK has a market cap of 126.3B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while SYK trades at $329.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas SYK's P/E ratio is 24.59. In terms of profitability, LUNG's ROE is -0.97%, compared to SYK's ROE of +0.16%. Regarding short-term risk, LUNG is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check SYK's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, MDT has a market cap of 119.5B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while MDT trades at $93.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas MDT's P/E ratio is 16.88. In terms of profitability, LUNG's ROE is -0.97%, compared to MDT's ROE of +0.10%. Regarding short-term risk, LUNG is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check MDT's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, BSX has a market cap of 74.9B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while BSX trades at $50.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas BSX's P/E ratio is 16.25. In terms of profitability, LUNG's ROE is -0.97%, compared to BSX's ROE of +0.15%. Regarding short-term risk, LUNG is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check BSX's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, EW has a market cap of 51.7B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while EW trades at $89.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas EW's P/E ratio is 33.26. In terms of profitability, LUNG's ROE is -0.97%, compared to EW's ROE of +0.10%. Regarding short-term risk, LUNG is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check EW's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, DXCM has a market cap of 34.8B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while DXCM trades at $92.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas DXCM's P/E ratio is 36.21. In terms of profitability, LUNG's ROE is -0.97%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, LUNG is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check DXCM's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, GEHC has a market cap of 33.8B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while GEHC trades at $74.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas GEHC's P/E ratio is 16.41. In terms of profitability, LUNG's ROE is -0.97%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, LUNG is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check GEHC's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, RMD has a market cap of 33.6B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while RMD trades at $231.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas RMD's P/E ratio is 21.49. In terms of profitability, LUNG's ROE is -0.97%, compared to RMD's ROE of +0.24%. Regarding short-term risk, LUNG is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check RMD's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, PHG has a market cap of 26.8B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while PHG trades at $27.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas PHG's P/E ratio is 15.67. In terms of profitability, LUNG's ROE is -0.97%, compared to PHG's ROE of +0.10%. Regarding short-term risk, LUNG is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check PHG's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, ZBH has a market cap of 19.5B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while ZBH trades at $100.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas ZBH's P/E ratio is 11.91. In terms of profitability, LUNG's ROE is -0.97%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, LUNG is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check ZBH's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas ABMD's P/E ratio is 65.36. In terms of profitability, LUNG's ROE is -0.97%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, LUNG is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check ABMD's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, PEN has a market cap of 12.8B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while PEN trades at $325.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas PEN's P/E ratio is 84.91. In terms of profitability, LUNG's ROE is -0.97%, compared to PEN's ROE of +0.11%. Regarding short-term risk, LUNG is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check PEN's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas SWAV's P/E ratio is 78.76. In terms of profitability, LUNG's ROE is -0.97%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, LUNG is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check SWAV's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, SNN has a market cap of 12.3B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while SNN trades at $29.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas SNN's P/E ratio is 13.77. In terms of profitability, LUNG's ROE is -0.97%, compared to SNN's ROE of +0.12%. Regarding short-term risk, LUNG is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check SNN's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, GMED has a market cap of 11.7B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while GMED trades at $86.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas GMED's P/E ratio is 19.58. In terms of profitability, LUNG's ROE is -0.97%, compared to GMED's ROE of +0.12%. Regarding short-term risk, LUNG is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check GMED's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, ALGN has a market cap of 11.6B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while ALGN trades at $162.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas ALGN's P/E ratio is 14.82. In terms of profitability, LUNG's ROE is -0.97%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, LUNG is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check ALGN's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, GKOS has a market cap of 10.9B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while GKOS trades at $184.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas GKOS's P/E ratio is -214.86. In terms of profitability, LUNG's ROE is -0.97%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, LUNG is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check GKOS's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, PODD has a market cap of 10.3B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while PODD trades at $148.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas PODD's P/E ratio is 25.24. In terms of profitability, LUNG's ROE is -0.97%, compared to PODD's ROE of +0.27%. Regarding short-term risk, LUNG is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check PODD's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, BIO has a market cap of 10.2B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while BIO trades at $380.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas BIO's P/E ratio is 40.94. In terms of profitability, LUNG's ROE is -0.97%, compared to BIO's ROE of +0.03%. Regarding short-term risk, LUNG is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check BIO's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, BIO-B has a market cap of 10B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while BIO-B trades at $365.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas BIO-B's P/E ratio is -64.28. In terms of profitability, LUNG's ROE is -0.97%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, LUNG is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check BIO-B's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while MASI trades at $179.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas MASI's P/E ratio is 44.43. In terms of profitability, LUNG's ROE is -0.97%, compared to MASI's ROE of +0.09%. Regarding short-term risk, LUNG is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check MASI's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, BRKR has a market cap of 9.1B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while BRKR trades at $59.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas BRKR's P/E ratio is 29.93. In terms of profitability, LUNG's ROE is -0.97%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, LUNG is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check BRKR's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, BRKRP has a market cap of 8.8B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while BRKRP trades at $439.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas BRKRP's P/E ratio is 238.80. In terms of profitability, LUNG's ROE is -0.97%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, LUNG is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check BRKRP's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, HAE has a market cap of 4.9B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while HAE trades at $108.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas HAE's P/E ratio is 21.71. In terms of profitability, LUNG's ROE is -0.97%, compared to HAE's ROE of +0.11%. Regarding short-term risk, LUNG is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check HAE's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas NARI's P/E ratio is -59.24. In terms of profitability, LUNG's ROE is -0.97%, compared to NARI's ROE of -0.00%. Regarding short-term risk, LUNG is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check NARI's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, LIVN has a market cap of 4.3B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while LIVN trades at $78.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas LIVN's P/E ratio is 18.70. In terms of profitability, LUNG's ROE is -0.97%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, LUNG is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check LIVN's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while ITGR trades at $125.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas ITGR's P/E ratio is 19.71. In terms of profitability, LUNG's ROE is -0.97%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, LUNG is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check ITGR's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, IRTC has a market cap of 4.2B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while IRTC trades at $128.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas IRTC's P/E ratio is -200.81. In terms of profitability, LUNG's ROE is -0.97%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, LUNG is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check IRTC's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas AXNX's P/E ratio is -709.80. In terms of profitability, LUNG's ROE is -0.97%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, LUNG is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check AXNX's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, TMDX has a market cap of 3.3B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while TMDX trades at $94.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas TMDX's P/E ratio is 48.06. In terms of profitability, LUNG's ROE is -0.97%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, LUNG is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check TMDX's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, AXGN has a market cap of 2.7B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while AXGN trades at $50.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas AXGN's P/E ratio is 132.63. In terms of profitability, LUNG's ROE is -0.97%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, LUNG is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for LUNG.Check AXGN's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, BFLY has a market cap of 2.5B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while BFLY trades at $9.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas BFLY's P/E ratio is -39.79. In terms of profitability, LUNG's ROE is -0.97%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, LUNG is more volatile compared to BFLY. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check BFLY's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, UFPT has a market cap of 2.4B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while UFPT trades at $309.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas UFPT's P/E ratio is 31.58. In terms of profitability, LUNG's ROE is -0.97%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, LUNG is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check UFPT's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while ESTA trades at $72.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas ESTA's P/E ratio is -57.67. In terms of profitability, LUNG's ROE is -0.97%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, LUNG is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check ESTA's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas NUVA's P/E ratio is 75.00. In terms of profitability, LUNG's ROE is -0.97%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, LUNG is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check NUVA's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, NVCR has a market cap of 2B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while NVCR trades at $17.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas NVCR's P/E ratio is -11.18. In terms of profitability, LUNG's ROE is -0.97%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, LUNG is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check NVCR's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, INSP has a market cap of 1.8B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while INSP trades at $62.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas INSP's P/E ratio is 27.51. In terms of profitability, LUNG's ROE is -0.97%, compared to INSP's ROE of +0.18%. Regarding short-term risk, LUNG is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check INSP's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while CNMD trades at $51.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas CNMD's P/E ratio is 11.29. In terms of profitability, LUNG's ROE is -0.97%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, LUNG is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check CNMD's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, TNDM has a market cap of 1.5B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while TNDM trades at $22.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas TNDM's P/E ratio is -24.00. In terms of profitability, LUNG's ROE is -0.97%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, LUNG is more volatile compared to TNDM. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check TNDM's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, ENOV has a market cap of 1.5B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while ENOV trades at $26.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas ENOV's P/E ratio is 7.46. In terms of profitability, LUNG's ROE is -0.97%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, LUNG is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check ENOV's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while ATEC trades at $9.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas ATEC's P/E ratio is -158.00. In terms of profitability, LUNG's ROE is -0.97%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, LUNG is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check ATEC's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, AORT has a market cap of 1.4B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while AORT trades at $28.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas AORT's P/E ratio is 46.82. In terms of profitability, LUNG's ROE is -0.97%, compared to AORT's ROE of -0.01%. Regarding short-term risk, LUNG is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check AORT's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas HSKA's P/E ratio is -62.49. In terms of profitability, LUNG's ROE is -0.97%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, LUNG is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check HSKA's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while IART trades at $16.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas IART's P/E ratio is 7.09. In terms of profitability, LUNG's ROE is -0.97%, compared to IART's ROE of -0.01%. Regarding short-term risk, LUNG is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check IART's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while PRCT trades at $21.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas PRCT's P/E ratio is -11.18. In terms of profitability, LUNG's ROE is -0.97%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, LUNG is more volatile compared to PRCT. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check PRCT's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, LMRI has a market cap of 1.2B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while LMRI trades at $12.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas LMRI's P/E ratio is -24.16. In terms of profitability, LUNG's ROE is -0.97%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, LUNG is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for LUNG.Check LMRI's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while AVNS trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas AVNS's P/E ratio is 27.77. In terms of profitability, LUNG's ROE is -0.97%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, LUNG is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check AVNS's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while IRMD trades at $87.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas IRMD's P/E ratio is 44.15. In terms of profitability, LUNG's ROE is -0.97%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, LUNG is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check IRMD's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas SILK's P/E ratio is -18.96. In terms of profitability, LUNG's ROE is -0.97%, compared to SILK's ROE of -0.35%. Regarding short-term risk, LUNG is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check SILK's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas FNA's P/E ratio is -19.83. In terms of profitability, LUNG's ROE is -0.97%, compared to FNA's ROE of -0.35%. Regarding short-term risk, LUNG is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check FNA's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, BVS has a market cap of 974.2M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while BVS trades at $14.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas BVS's P/E ratio is 18.92. In terms of profitability, LUNG's ROE is -0.97%, compared to BVS's ROE of +0.28%. Regarding short-term risk, LUNG is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check BVS's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, CBLL has a market cap of 922.4M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while CBLL trades at $24.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas CBLL's P/E ratio is -14.91. In terms of profitability, LUNG's ROE is -0.97%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, LUNG is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check CBLL's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, SIBN has a market cap of 885.2M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while SIBN trades at $19.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas SIBN's P/E ratio is -58.71. In terms of profitability, LUNG's ROE is -0.97%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, LUNG is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check SIBN's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, AVR has a market cap of 873.1M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while AVR trades at $8.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas AVR's P/E ratio is -4.03. In terms of profitability, LUNG's ROE is -0.97%, compared to AVR's ROE of -0.78%. Regarding short-term risk, LUNG is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check AVR's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, INMD has a market cap of 865.7M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while INMD trades at $15.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas INMD's P/E ratio is 10.46. In terms of profitability, LUNG's ROE is -0.97%, compared to INMD's ROE of +0.12%. Regarding short-term risk, LUNG is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check INMD's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, BBNX has a market cap of 857.1M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while BBNX trades at $19.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas BBNX's P/E ratio is -12.62. In terms of profitability, LUNG's ROE is -0.97%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, LUNG is more volatile compared to BBNX. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check BBNX's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas CSII's P/E ratio is -20.83. In terms of profitability, LUNG's ROE is -0.97%, compared to CSII's ROE of -0.14%. Regarding short-term risk, LUNG is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check CSII's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, VREX has a market cap of 779.3M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while VREX trades at $18.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas VREX's P/E ratio is 19.48. In terms of profitability, LUNG's ROE is -0.97%, compared to VREX's ROE of +0.05%. Regarding short-term risk, LUNG is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check VREX's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, AHCO has a market cap of 766M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while AHCO trades at $5.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas AHCO's P/E ratio is 11.49. In terms of profitability, LUNG's ROE is -0.97%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, LUNG is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check AHCO's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, SSII has a market cap of 717.5M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while SSII trades at $3.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas SSII's P/E ratio is -69.92. In terms of profitability, LUNG's ROE is -0.97%, compared to SSII's ROE of -0.27%. Regarding short-term risk, LUNG is more volatile compared to SSII. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check SSII's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, KIDS has a market cap of 658.8M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while KIDS trades at $25.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas KIDS's P/E ratio is -21.74. In terms of profitability, LUNG's ROE is -0.97%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, LUNG is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check KIDS's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas SRDX's P/E ratio is -34.66. In terms of profitability, LUNG's ROE is -0.97%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, LUNG is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check SRDX's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, CTKB has a market cap of 601.8M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while CTKB trades at $4.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas CTKB's P/E ratio is -24.69. In terms of profitability, LUNG's ROE is -0.97%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, LUNG is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check CTKB's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, DCTH has a market cap of 591.7M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while DCTH trades at $17.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas DCTH's P/E ratio is 1714.00. In terms of profitability, LUNG's ROE is -0.97%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, LUNG is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check DCTH's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas APEN's P/E ratio is -9.43. In terms of profitability, LUNG's ROE is -0.97%, compared to APEN's ROE of -0.85%. Regarding short-term risk, LUNG is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check APEN's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, CERS has a market cap of 562.3M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while CERS trades at $2.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas CERS's P/E ratio is -55.69. In terms of profitability, LUNG's ROE is -0.97%, compared to CERS's ROE of -0.10%. Regarding short-term risk, LUNG is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check CERS's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, TCMD has a market cap of 537.3M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while TCMD trades at $23.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas TCMD's P/E ratio is 22.06. In terms of profitability, LUNG's ROE is -0.97%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, LUNG is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check TCMD's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, LUNG's ROE is -0.97%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, LUNG is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check ZIMV's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, NPCE has a market cap of 478.3M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while NPCE trades at $14.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas NPCE's P/E ratio is -24.61. In terms of profitability, LUNG's ROE is -0.97%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, LUNG is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check NPCE's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, CLPT has a market cap of 455.5M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while CLPT trades at $15.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas CLPT's P/E ratio is -12.87. In terms of profitability, LUNG's ROE is -0.97%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, LUNG is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check CLPT's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, SGHT has a market cap of 449.4M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while SGHT trades at $8.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas SGHT's P/E ratio is -14.75. In terms of profitability, LUNG's ROE is -0.97%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, LUNG is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check SGHT's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, CARL has a market cap of 448.6M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while CARL trades at $16.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas CARL's P/E ratio is -11.54. In terms of profitability, LUNG's ROE is -0.97%, compared to CARL's ROE of -0.38%. Regarding short-term risk, LUNG is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for LUNG.Check CARL's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, PACB has a market cap of 427.1M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while PACB trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas PACB's P/E ratio is -3.35. In terms of profitability, LUNG's ROE is -0.97%, compared to PACB's ROE of -49.62%. Regarding short-term risk, LUNG is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for LUNG.Check PACB's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, SENS has a market cap of 405.8M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while SENS trades at $9.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas SENS's P/E ratio is -4.35. In terms of profitability, LUNG's ROE is -0.97%, compared to SENS's ROE of -1.66%. Regarding short-term risk, LUNG is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for LUNG.Check SENS's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, OFIX has a market cap of 404.6M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while OFIX trades at $10.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas OFIX's P/E ratio is -13.08. In terms of profitability, LUNG's ROE is -0.97%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, LUNG is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check OFIX's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, CATX has a market cap of 367.2M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while CATX trades at $3.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas CATX's P/E ratio is -2.42. In terms of profitability, LUNG's ROE is -0.97%, compared to CATX's ROE of -0.42%. Regarding short-term risk, LUNG is more volatile compared to CATX. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check CATX's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, ELMD has a market cap of 327.5M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while ELMD trades at $39.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas ELMD's P/E ratio is 33.80. In terms of profitability, LUNG's ROE is -0.97%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, LUNG is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check ELMD's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, TLSI has a market cap of 324.5M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while TLSI trades at $5.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas TLSI's P/E ratio is -3.14. In terms of profitability, LUNG's ROE is -0.97%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, LUNG is more volatile compared to TLSI. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check TLSI's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas SMLR's P/E ratio is 3.92. In terms of profitability, LUNG's ROE is -0.97%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, LUNG is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check SMLR's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, CV has a market cap of 300.8M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while CV trades at $6.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas CV's P/E ratio is -2.41. In terms of profitability, LUNG's ROE is -0.97%, compared to CV's ROE of -1.78%. Regarding short-term risk, LUNG is more volatile compared to CV. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check CV's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, TMCI has a market cap of 281.5M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while TMCI trades at $4.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas TMCI's P/E ratio is -4.62. In terms of profitability, LUNG's ROE is -0.97%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, LUNG is more volatile compared to TMCI. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check TMCI's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, RXST has a market cap of 258.7M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while RXST trades at $6.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas RXST's P/E ratio is -5.53. In terms of profitability, LUNG's ROE is -0.97%, compared to RXST's ROE of -0.17%. Regarding short-term risk, LUNG is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check RXST's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, RCEL has a market cap of 249.9M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while RCEL trades at $10.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas RCEL's P/E ratio is -6.99. In terms of profitability, LUNG's ROE is -0.97%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, LUNG is more volatile compared to RCEL. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check RCEL's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, PROF has a market cap of 246.7M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while PROF trades at $6.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas PROF's P/E ratio is -6.93. In terms of profitability, LUNG's ROE is -0.97%, compared to PROF's ROE of -0.56%. Regarding short-term risk, LUNG is more volatile compared to PROF. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check PROF's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas MGRM's P/E ratio is -12.00. In terms of profitability, LUNG's ROE is -0.97%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, LUNG is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check MGRM's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas NVRO's P/E ratio is -1.91. In terms of profitability, LUNG's ROE is -0.97%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, LUNG is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check NVRO's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, STIM has a market cap of 208.8M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while STIM trades at $3.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas STIM's P/E ratio is -6.82. In terms of profitability, LUNG's ROE is -0.97%, compared to STIM's ROE of -1.51%. Regarding short-term risk, LUNG is more volatile compared to STIM. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check STIM's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas BSGM's P/E ratio is -5.81. In terms of profitability, LUNG's ROE is -0.97%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, LUNG is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for LUNG.Check BSGM's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, LUCD has a market cap of 184M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while LUCD trades at $0.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas LUCD's P/E ratio is -2.61. In terms of profitability, LUNG's ROE is -0.97%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, LUNG is more volatile compared to LUCD. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check LUCD's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas MDGS's P/E ratio is -0.27. In terms of profitability, LUNG's ROE is -0.97%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, LUNG is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for LUNG.Check MDGS's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, QSI has a market cap of 165.2M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while QSI trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas QSI's P/E ratio is -1.82. In terms of profitability, LUNG's ROE is -0.97%, compared to QSI's ROE of -0.47%. Regarding short-term risk, LUNG is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for LUNG.Check QSI's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas QIPT's P/E ratio is -15.87. In terms of profitability, LUNG's ROE is -0.97%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, LUNG is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check QIPT's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, FOCL has a market cap of 154.8M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while FOCL trades at $4.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas FOCL's P/E ratio is -3.99. In terms of profitability, LUNG's ROE is -0.97%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, LUNG is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check FOCL's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, INGN has a market cap of 151.9M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while INGN trades at $5.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas INGN's P/E ratio is -6.16. In terms of profitability, LUNG's ROE is -0.97%, compared to INGN's ROE of -0.13%. Regarding short-term risk, LUNG is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check INGN's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, QTRX has a market cap of 140.8M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while QTRX trades at $2.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas QTRX's P/E ratio is -1.18. In terms of profitability, LUNG's ROE is -0.97%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, LUNG is more volatile compared to QTRX. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check QTRX's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, LNSR has a market cap of 106.6M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while LNSR trades at $8.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas LNSR's P/E ratio is 8.86. In terms of profitability, LUNG's ROE is -0.97%, compared to LNSR's ROE of +103.80%. Regarding short-term risk, LUNG is more volatile compared to LNSR. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check LNSR's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas ICAD's P/E ratio is -20.37. In terms of profitability, LUNG's ROE is -0.97%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, LUNG is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check ICAD's competition here

Pulmonx Corporation (NASDAQ: LUNG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LUNG stands at 95.5M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, LUNG is priced at $2.26 on the NASDAQ, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LUNG currently has a P/E ratio of -1.95, whereas HJLI's P/E ratio is N/A. In terms of profitability, LUNG's ROE is -0.97%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, LUNG is more volatile compared to HJLI. This indicates higher risk in terms of short-term price fluctuations for LUNG.Check HJLI's competition here